144186-11-8

Basic information

• Product Name: METHYL 6-[(TERT-BUTOXYCARBONYL)AMINO]NICOTINATE
• Synonyms: METHYL 6-[(TERT-BUTOXYCARBONYL)AMINO]NICOTINATE;6-TERT-BUTOXYCARBONYLAMINO-NICOTINIC ACID METHYL ESTER;Methyl 6-[(tert-butoxycarbonyl)amino]nicotinate ,95%;3-Pyridinecarboxylic acid, 6-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester;Methyl 6-((tert-butoxycarbonyl)
• CAS NO: 144186-11-8
• Molecular Formula: C12H16N2O4
• Molecular Weight: 252.27
• Product Categories: Heterocyclic Building Blocks
• Mol File: 144186-11-8.mol

Chemical Properties

• Melting Point: 166-170°C
• Boiling Point: 320.9±27.0 °C(Predicted)
• Appearance: /
• Density: 1.203±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.98±0.70(Predicted)
• CAS DataBase Reference: METHYL 6-[(TERT-BUTOXYCARBONYL)AMINO]NICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-[(TERT-BUTOXYCARBONYL)AMINO]NICOTINATE(144186-11-8)
• EPA Substance Registry System: METHYL 6-[(TERT-BUTOXYCARBONYL)AMINO]NICOTINATE(144186-11-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 144186-11-8(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Upstream product

• 36052-24-1 methyl 6-aminonicotinoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 93-60-7 methyl 3-pyridinecarboxylate 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 3167-49-5 6-aminonicotinic acid 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 1258197-10-2 C₁₈H₂₀ClN₃O₃ 
• 1258197-11-3 C₂₃H₂₄Cl₂N₆O₃ 
• 1258197-12-4 C₂₉H₃₇ClN₈O₄ 
• 1258197-03-3 C₂₄H₂₉ClN₈O₂ 
• 1258197-13-5 C₁₃H₁₂ClN₃O 
• 1258197-14-6 C₁₈H₁₆Cl₂N₆O 
• 1258197-04-4 C₂₄H₂₉ClN₈O₂ 
• 1258197-16-8 C₂₆H₃₁ClN₈O₃ 
• 1258197-05-5 C₂₁H₂₃ClN₈O 
• 199296-40-7 2-(tert-butyloxycarbonyl)-aminopyridine-5-carboxaldehyde 
• 827587-90-6 (6-aminopyridin-3-yl)(morpholin-4-yl)methanone 
• 231958-14-8 6-[(tert-butoxycarbonyl)amino]nicotinic acid 
• 144186-12-9 carbonic acid 6-tert-butoxycarbonylamino-pyridin-3-ylmethyl ester 4-nitro-phenyl ester 
• 169280-83-5 (5-hydroxymethylpyridin-2-yl)-carbamic acid t-butyl ester 

Relevant articles and documents

A multifunctional reagent designed for the site-selective amination of pyridines

We report the development of a multifunctional reagent for the direct conversion of pyridines to Boc-protected 2-aminopyridines with exquisite site selectivity and chemoselectivity. The novel reagent was prepared on 200-g scale in a single step, reacts in the title reaction under mild conditions without precautions toward air or moisture, and is tolerant of nearly all common functionality. Experimental and in situ spectroscopic monitoring techniques provide detailed insights and unexpected findings for the unique reaction mechanism.

PROBES FOR IMAGING HUNTINGTIN PROTEIN

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

BETA-LACTAMASE INHIBITORS

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

The present invention comprises inter alia triazine compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS

Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.